SIC
MRNA icon

SJS Investment Consulting’s Moderna MRNA Stock Holding History

SJS Investment Consulting’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.5K Buy
193
+178
+1,187% +$9.21K ﹤0.01% 951
2026
Q1 		$762 Buy
+15
New +$700 ﹤0.01% 1584
2024
Q4 		– Sell
-20
Closed -$1.34K – 1668
2024
Q3 		$1.34K Buy
20
+1
+5% +$92 ﹤0.01% 965
2024
Q2 		$2.26K Buy
19
+2
+12% +$253 ﹤0.01% 656
2024
Q1 		$1.81K Buy
17
+1
+6% +$101 ﹤0.01% 797
2023
Q4 		$1.59K Sell
16
-7
-30% -$589 ﹤0.01% 760
2023
Q3 		$2.38K Buy
23
+10
+77% +$1.11K ﹤0.01% 568
2023
Q2 		$1.58K Buy
13
+7
+117% +$934 ﹤0.01% 696
2023
Q1 		$922 Sell
6
-13
-68% -$2.15K ﹤0.01% 927
2022
Q4 		$3.41K Buy
19
+12
+171% +$1.96K ﹤0.01% 435
2022
Q3 		$1K Buy
+7
New +$1.06K ﹤0.01% 824
2022
Q1 		$43K Hold
252
– – 0.01% 194
2021
Q4 		$64K Buy
+252
New +$73.7K 0.02% 155

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

SJS Investment Consulting's MRNA Position: Q2 2026 in Review

SJS Investment Consulting increased its Moderna (MRNA) stake by 1,187% in Q2 2026, buying an estimated $9.21K and bringing the position to 193 shares worth $13.5K. The position accounts for ﹤0.01% of the portfolio, ranked #951.

SJS Investment Consulting first reported a position in MRNA in Q4 2021 and has held it in 13 quarters since. The position peaked at $64K in Q4 2021. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • SJS Investment Consulting held 193 shares of Moderna worth $13.5K as of Q2 2026.
  • SJS Investment Consulting bought 178 Moderna shares in Q2 2026, an estimated $9.21K.
  • Moderna made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #951 holding.
  • SJS Investment Consulting first reported a position in Moderna in Q4 2021 and has held it in 13 quarters since.
  • SJS Investment Consulting's Moderna position peaked at $64K in Q4 2021.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.